Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;28(2):e32.
doi: 10.3802/jgo.2017.28.e32. Epub 2017 Feb 10.

Clinical statistics of gynecologic cancers in Japan

Wataru Yamagami  1   2 , Satoru Nagase  2   3 , Fumiaki Takahashi  4 , Kazuhiko Ino  2   5 , Toru Hachisuga  2   6 , Daisuke Aoki  2   7 , Hidetaka Katabuchi  2   8
Affiliations
Review

Clinical statistics of gynecologic cancers in Japan

Wataru Yamagami et al. J Gynecol Oncol. 2017 Mar.

Abstract

Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve-point six percent of ovarian cancer patients received neoadjuvant chemotherapy.

Keywords: Genital Neoplasms, Female; Japan; Mortality; Neoplasms; Prevalence; Registries; Stage.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Incidence and mortality of gynecologic malignancies in Japan. (A) Incidence of gynecologic malignancies (cervical, endometrial, and ovarian cancers). (B) Age-adjusted mortality of gynecologic malignancies (cervical, endometrial, and ovarian cancers).
Fig. 2
Fig. 2
Characteristics of cervical cancer. (A) Distribution of clinical stages in cervical cancer. (B) Distribution of clinical stages in younger or elder patients with cervical cancer. (C) Distribution of histological types in cervical cancer. (D) Distribution of treatment methods in cervical cancer.
Fig. 3
Fig. 3
Characteristics of endometrial cancer. (A) Distribution of post-surgical stages in endometrial cancer. (B) Distribution of post-surgical stages in both younger and older patients with endometrial cancer. (C) Distribution of histological types in endometrial cancer. (D) Distribution of treatment methods in endometrial cancer.
Fig. 4
Fig. 4
Characteristics of ovarian malignant tumor. (A) Distribution of post-surgical stages in ovarian malignant tumor. (B) Distribution of post-surgical stages in younger and older patients with ovarian malignant cancer. (C) Distribution of histological types in ovarian malignant cancer. (D) Distribution of treatment methods in ovarian malignant cancer.
See this image and copyright information in PMC

References

    1. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45:884–891. - PubMed
    1. Cancer Information Services (JP) Cancer statistics in Japan [Internet] Tokyo: National Cancer Center Japan; 2016. [cited 2016 Dec 22]. Available from: http://ganjoho.jp/reg_stat/statistics/dl/index.html.
    1. Inaba N. The patient annual report in 2005. Acta Obstet Gynaecol Jpn. 2007;59:901–982. Available from: http://fa.kyorin.co.jp/jsog/readPDF.php?file=to63/59/3/KJ00005049882.pdf.
    1. Aoki Y. The patient annual report in 2010. Acta Obstet Gynaecol Jpn. 2012;64:1029–1077. Available from: http://fa.kyorin.co.jp/jsog/readPDF.php?file=64/3/064031029.pdf.
    1. Aoki D. The patient annual report in 2012. Acta Obstet Gynaecol Jpn. 2014;66:995–1038. Available from: http://fa.kyorin.co.jp/jsog/readPDF.php?file=66/3/066030995.pdf.

MeSH terms